(AOF) –
Berkem
The specialist in plant chemicals will publish its turnover for the fourth quarter.
Elis
The industrial laundry group Elis today published a “record” annual turnover for 2022, at 3.82 billion euros. The group, which provides rental-maintenance solutions for textile, hygiene and well-being items, present in Europe and Latin America, anticipates organic revenue growth in 2023 of more than 10%, following a year 2022 marked by the recovery of the hotel industry. The 2022 net current result per share is still expected above 1.45 euros.
Neolife
The French manufacturer of low-carbon building solutions will announce its fourth quarter sales.
Lumibird
Lumibird has unveiled 2022 revenue of 191 million euros, up 18%, of which 12% at constant scope and exchange rates. The European specialist in laser technologies recorded a new record in the fourth quarter with a turnover of 66 million euros, an increase of 32%. The Photonics division experienced the strongest growth over the last quarter, at +49% with a turnover of 35.3 million euros. The Medical division closed the last quarter on an increase of 17% to 30.7 million euros.
Ober
The specialist in decorative and technical solutions for interior fittings will reveal its turnover for the fourth quarter.
Ribs
The supplier for the semiconductor sector will report its fourth quarter sales.
Seb
Seb’s sales in 2022 fell by 1.2% to 7.96 billion euros. The specialist in small household appliances and cookware recorded a drop in its activity of 4.7% like-for-like. “The group’s business held up well in most of the geographic areas in which it operates, and the fourth quarter showed a slightly more favorable business trend,” said Stanislas de Gramont, Group CEO. Over this period, revenues reached 2.4 billion euros, down 5.6% like-for-like.
Wavestone
In the third quarter, ending at the end of December, of the 2022/23 financial year, Wavestone recorded consolidated revenue of 139.1 million euros, up 14%. At constant exchange rates and scope, sales increased by 6%. The day effect was unfavorable over the past quarter and stood at -1.6%. The activity rate fell over this period, under the effect of the numerous arrivals of new employees since September. Over nine months, the rate thus stood at 74%, compared to 75% in the first half of the financial year.
Valbotis
The biotech Valbiotis announces the positive results of the clinical study of bioavailability and mode of action carried out on Totum 854 once morest arterial hypertension, the first cardiovascular risk factor in the world. Valbiotis aims to sign international partnerships and will market itself on the French market: the company stresses that the market for mild to moderate arterial hypertension today concerns 123 million adults in the United States and Europe.
